CellCarta and Imagene AI expanded collaboration to support AI-powered biomarker and companion diagnostic (CDx) development, focusing on non-small cell lung cancer (NSCLC). The partnership aims to address a recurring bottleneck in AI biomarker translation: moving from an algorithm to analytical validation, trial enrollment logistics, and regulatory submission readiness. The companies said their work covers assay validation, clinical deployment, regulatory support, and program coordination across development to submission. Imagene AI’s Lung Prediction Panel is positioned for biomarker applications, with programs described as coordinated for unnamed global pharmaceutical partners. For biotech, the update highlights how “AI-pathology to CDx” is becoming a resourcing and regulatory expertise problem—not just a model performance problem—requiring end-to-end operational capability for prospective studies and analytical qualification.